APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

HIV Prevention Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global HIV Prevention Drug Market Analysis and Forecast 2026-2032

Report ID 173998810229 December 2025195 pages

Choose your research edition.

Industry ResearchHIV Prevention Drug Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV Prevention Drug Industry Growth and Trends Forecast to 203276 pages · $3,450 USDMarket StructureGlobal HIV Prevention Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV Prevention Drug Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV Prevention Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global HIV Prevention Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for HIV Prevention Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for HIV Prevention Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for HIV Prevention Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for HIV Prevention Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of HIV Prevention Drug include Gilead Sciences and ViiV Healthcare etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for HIV Prevention Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of HIV Prevention Drug, also provides the sales of main regions and countries. Of the upcoming market potential for HIV Prevention Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the HIV Prevention Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global HIV Prevention Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for HIV Prevention Drug sales, projected growth trends, production technology, application and end-user industry.

HIV Prevention Drug Segment by Company

Gilead Sciences

ViiV Healthcare

HIV Prevention Drug Segment by Type

Lenacapavir

Cabotegravir

HIV Prevention Drug Segment by Application

Hospital

Clinic

Others

HIV Prevention Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Prevention Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV Prevention Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Prevention Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of HIV Prevention Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of HIV Prevention Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, HIV Prevention Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global HIV Prevention Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Lenacapavir Major Manufacturers Table 3. Cabotegravir Major Manufacturers Table 4. Global HIV Prevention Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Manufacturers Table 6. Clinic Major Manufacturers Table 7. Others Major Manufacturers Table 8. HIV Prevention Drug Industry Trends Table 9. HIV Prevention Drug Industry Drivers Table 10. HIV Prevention Drug Industry Opportunities and Challenges Table 11. HIV Prevention Drug Industry Restraints Table 12. Global HIV Prevention Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global HIV Prevention Drug Revenue by Region (2021-2026) & (US$ Million) Table 14. Global HIV Prevention Drug Revenue by Region (2027-2032) & (US$ Million) Table 15. Global HIV Prevention Drug Revenue Market Share by Region (2021-2026) Table 16. Global HIV Prevention Drug Revenue Market Share by Region (2027-2032) Table 17. Global HIV Prevention Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global HIV Prevention Drug Sales by Region (2021-2026) & (K Units) Table 19. Global HIV Prevention Drug Sales by Region (2027-2032) & (K Units) Table 20. Global HIV Prevention Drug Sales Market Share by Region (2021-2026) Table 21. Global HIV Prevention Drug Sales Market Share by Region (2027-2032) Table 22. Global HIV Prevention Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global HIV Prevention Drug Revenue Market Share by Manufacturers (2021-2026) Table 24. Global HIV Prevention Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global HIV Prevention Drug Sales Market Share by Manufacturers (2021-2026) Table 26. Global HIV Prevention Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global HIV Prevention Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global HIV Prevention Drug Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global HIV Prevention Drug Manufacturers, Product Type & Application Table 30. Global HIV Prevention Drug Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global HIV Prevention Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global HIV Prevention Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global HIV Prevention Drug Revenue by Type (2021-2026) & (US$ Million) Table 35. Global HIV Prevention Drug Revenue by Type (2027-2032) & (US$ Million) Table 36. Global HIV Prevention Drug Revenue Market Share by Type (2021-2026) Table 37. Global HIV Prevention Drug Revenue Market Share by Type (2027-2032) Table 38. Global HIV Prevention Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global HIV Prevention Drug Sales by Type (2021-2026) & (K Units) Table 40. Global HIV Prevention Drug Sales by Type (2027-2032) & (K Units) Table 41. Global HIV Prevention Drug Sales Market Share by Type (2021-2026) Table 42. Global HIV Prevention Drug Sales Market Share by Type (2027-2032) Table 43. Global HIV Prevention Drug Price by Type (2021-2026) & (US$/Unit) Table 44. Global HIV Prevention Drug Price by Type (2027-2032) & (US$/Unit) Table 45. Global HIV Prevention Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global HIV Prevention Drug Revenue by Application (2021-2026) & (US$ Million) Table 47. Global HIV Prevention Drug Revenue by Application (2027-2032) & (US$ Million) Table 48. Global HIV Prevention Drug Revenue Market Share by Application (2021-2026) Table 49. Global HIV Prevention Drug Revenue Market Share by Application (2027-2032) Table 50. Global HIV Prevention Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global HIV Prevention Drug Sales by Application (2021-2026) & (K Units) Table 52. Global HIV Prevention Drug Sales by Application (2027-2032) & (K Units) Table 53. Global HIV Prevention Drug Sales Market Share by Application (2021-2026) Table 54. Global HIV Prevention Drug Sales Market Share by Application (2027-2032) Table 55. Global HIV Prevention Drug Price by Application (2021-2026) & (US$/Unit) Table 56. Global HIV Prevention Drug Price by Application (2027-2032) & (US$/Unit) Table 57. Gilead Sciences Company Information Table 58. Gilead Sciences Business Overview Table 59. Gilead Sciences HIV Prevention Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Gilead Sciences HIV Prevention Drug Product Portfolio Table 61. Gilead Sciences Recent Development Table 62. ViiV Healthcare Company Information Table 63. ViiV Healthcare Business Overview Table 64. ViiV Healthcare HIV Prevention Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. ViiV Healthcare HIV Prevention Drug Product Portfolio Table 66. ViiV Healthcare Recent Development Table 67. North America HIV Prevention Drug Revenue by Type (2021-2026) & (US$ Million) Table 68. North America HIV Prevention Drug Revenue by Type (2027-2032) & (US$ Million) Table 69. North America HIV Prevention Drug Sales by Type (2021-2026) & (K Units) Table 70. North America HIV Prevention Drug Sales by Type (2027-2032) & (K Units) Table 71. North America HIV Prevention Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 72. North America HIV Prevention Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 73. North America HIV Prevention Drug Revenue by Application (2021-2026) & (US$ Million) Table 74. North America HIV Prevention Drug Revenue by Application (2027-2032) & (US$ Million) Table 75. North America HIV Prevention Drug Sales by Application (2021-2026) & (K Units) Table 76. North America HIV Prevention Drug Sales by Application (2027-2032) & (K Units) Table 77. North America HIV Prevention Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 78. North America HIV Prevention Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 79. North America HIV Prevention Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 80. North America HIV Prevention Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 81. North America HIV Prevention Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 82. North America HIV Prevention Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 83. North America HIV Prevention Drug Sales by Country (2021-2026) & (K Units) Table 84. North America HIV Prevention Drug Sales by Country (2027-2032) & (K Units) Table 85. North America HIV Prevention Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 86. North America HIV Prevention Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 87. United States HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 88. Canada HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 89. Mexico HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 90. Europe HIV Prevention Drug Revenue by Type (2021-2026) & (US$ Million) Table 91. Europe HIV Prevention Drug Revenue by Type (2027-2032) & (US$ Million) Table 92. Europe HIV Prevention Drug Sales by Type (2021-2026) & (K Units) Table 93. Europe HIV Prevention Drug Sales by Type (2027-2032) & (K Units) Table 94. Europe HIV Prevention Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 95. Europe HIV Prevention Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 96. Europe HIV Prevention Drug Revenue by Application (2021-2026) & (US$ Million) Table 97. Europe HIV Prevention Drug Revenue by Application (2027-2032) & (US$ Million) Table 98. Europe HIV Prevention Drug Sales by Application (2021-2026) & (K Units) Table 99. Europe HIV Prevention Drug Sales by Application (2027-2032) & (K Units) Table 100. Europe HIV Prevention Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 101. Europe HIV Prevention Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 102. Europe HIV Prevention Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Europe HIV Prevention Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 104. Europe HIV Prevention Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 105. Europe HIV Prevention Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 106. Europe HIV Prevention Drug Sales by Country (2021-2026) & (K Units) Table 107. Europe HIV Prevention Drug Sales by Country (2027-2032) & (K Units) Table 108. Europe HIV Prevention Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 109. Europe HIV Prevention Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 110. Germany HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 111. France HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 112. U.K. HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 113. Italy HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 114. Russia HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 115. Spain HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 116. Netherlands HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 117. Switzerland HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 118. Sweden HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 119. Poland HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 120. China HIV Prevention Drug Revenue by Type (2021-2026) & (US$ Million) Table 121. China HIV Prevention Drug Revenue by Type (2027-2032) & (US$ Million) Table 122. China HIV Prevention Drug Sales by Type (2021-2026) & (K Units) Table 123. China HIV Prevention Drug Sales by Type (2027-2032) & (K Units) Table 124. China HIV Prevention Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 125. China HIV Prevention Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 126. China HIV Prevention Drug Revenue by Application (2021-2026) & (US$ Million) Table 127. China HIV Prevention Drug Revenue by Application (2027-2032) & (US$ Million) Table 128. China HIV Prevention Drug Sales by Application (2021-2026) & (K Units) Table 129. China HIV Prevention Drug Sales by Application (2027-2032) & (K Units) Table 130. China HIV Prevention Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 131. China HIV Prevention Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 132. Asia HIV Prevention Drug Revenue by Type (2021-2026) & (US$ Million) Table 133. Asia HIV Prevention Drug Revenue by Type (2027-2032) & (US$ Million) Table 134. Asia HIV Prevention Drug Sales by Type (2021-2026) & (K Units) Table 135. Asia HIV Prevention Drug Sales by Type (2027-2032) & (K Units) Table 136. Asia HIV Prevention Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 137. Asia HIV Prevention Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 138. Asia HIV Prevention Drug Revenue by Application (2021-2026) & (US$ Million) Table 139. Asia HIV Prevention Drug Revenue by Application (2027-2032) & (US$ Million) Table 140. Asia HIV Prevention Drug Sales by Application (2021-2026) & (K Units) Table 141. Asia HIV Prevention Drug Sales by Application (2027-2032) & (K Units) Table 142. Asia HIV Prevention Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 143. Asia HIV Prevention Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 144. Asia HIV Prevention Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. Asia HIV Prevention Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 146. Asia HIV Prevention Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 147. Asia HIV Prevention Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 148. Asia HIV Prevention Drug Sales by Country (2021-2026) & (K Units) Table 149. Asia HIV Prevention Drug Sales by Country (2027-2032) & (K Units) Table 150. Asia HIV Prevention Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 151. Asia HIV Prevention Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 152. Japan HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 153. South Korea HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 154. India HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 155. Australia HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 156. Taiwan HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 157. Southeast Asia HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 158. SAMEA HIV Prevention Drug Revenue by Type (2021-2026) & (US$ Million) Table 159. SAMEA HIV Prevention Drug Revenue by Type (2027-2032) & (US$ Million) Table 160. SAMEA HIV Prevention Drug Sales by Type (2021-2026) & (K Units) Table 161. SAMEA HIV Prevention Drug Sales by Type (2027-2032) & (K Units) Table 162. SAMEA HIV Prevention Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 163. SAMEA HIV Prevention Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 164. SAMEA HIV Prevention Drug Revenue by Application (2021-2026) & (US$ Million) Table 165. SAMEA HIV Prevention Drug Revenue by Application (2027-2032) & (US$ Million) Table 166. SAMEA HIV Prevention Drug Sales by Application (2021-2026) & (K Units) Table 167. SAMEA HIV Prevention Drug Sales by Application (2027-2032) & (K Units) Table 168. SAMEA HIV Prevention Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 169. SAMEA HIV Prevention Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 170. SAMEA HIV Prevention Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 171. SAMEA HIV Prevention Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 172. SAMEA HIV Prevention Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 173. SAMEA HIV Prevention Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 174. SAMEA HIV Prevention Drug Sales by Country (2021-2026) & (K Units) Table 175. SAMEA HIV Prevention Drug Sales by Country (2027-2032) & (K Units) Table 176. SAMEA HIV Prevention Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 177. SAMEA HIV Prevention Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 178. Brazil HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 179. Argentina HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 180. Chile HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 181. Colombia HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 182. Peru HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 183. Saudi Arabia HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 184. Israel HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 185. UAE HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 186. Turkey HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 187. Iran HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 188. Egypt HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Table 189. Key Raw Materials Table 190. Raw Materials Key Suppliers Table 191. HIV Prevention Drug Distributors List Table 192. HIV Prevention Drug Customers List Table 193. Research Programs/Design for This Report Table 194. Authors List of This Report Table 195. Secondary Sources Table 196. Primary Sources List of Figures Figure 1. HIV Prevention Drug Image Figure 2. Global HIV Prevention Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV Prevention Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Lenacapavir Image Figure 5. Cabotegravir Image Figure 6. Global HIV Prevention Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global HIV Prevention Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Others Image Figure 11. Global HIV Prevention Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global HIV Prevention Drug Revenue (2021-2032) & (US$ Million) Figure 13. Global HIV Prevention Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global HIV Prevention Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global HIV Prevention Drug Revenue Market Share by Region (2021-2032) Figure 16. Global HIV Prevention Drug Sales (2021-2032) & (K Units) Figure 17. Global HIV Prevention Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global HIV Prevention Drug Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico HIV Prevention Drug Sales YoY (2021-2032) & (K Units) Figure 20. Europe HIV Prevention Drug Sales YoY (2021-2032) & (K Units) Figure 21. China HIV Prevention Drug Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) HIV Prevention Drug Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa HIV Prevention Drug Sales YoY (2021-2032) & (K Units) Figure 24. Global HIV Prevention Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global HIV Prevention Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global HIV Prevention Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global HIV Prevention Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global HIV Prevention Drug Revenue Market Share by Type (2021-2032) Figure 30. Global HIV Prevention Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global HIV Prevention Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global HIV Prevention Drug Sales Market Share by Type (2021-2032) Figure 33. Global HIV Prevention Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global HIV Prevention Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global HIV Prevention Drug Revenue Market Share by Application (2021-2032) Figure 36. Global HIV Prevention Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global HIV Prevention Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global HIV Prevention Drug Sales Market Share by Application (2021-2032) Figure 39. North America HIV Prevention Drug Revenue Share by Type (2021-2032) Figure 40. North America HIV Prevention Drug Sales Share by Type (2021-2032) Figure 41. North America HIV Prevention Drug Revenue Share by Application (2021-2032) Figure 42. North America HIV Prevention Drug Sales Share by Application (2021-2032) Figure 43. North America HIV Prevention Drug Revenue Share by Country (2021-2032) Figure 44. North America HIV Prevention Drug Sales Share by Country (2021-2032) Figure 45. Europe HIV Prevention Drug Revenue Share by Type (2021-2032) Figure 46. Europe HIV Prevention Drug Sales Share by Type (2021-2032) Figure 47. Europe HIV Prevention Drug Revenue Share by Application (2021-2032) Figure 48. Europe HIV Prevention Drug Sales Share by Application (2021-2032) Figure 49. Europe HIV Prevention Drug Revenue Share by Country (2021-2032) Figure 50. Europe HIV Prevention Drug Sales Share by Country (2021-2032) Figure 51. China HIV Prevention Drug Revenue Share by Type (2021-2032) Figure 52. China HIV Prevention Drug Sales Share by Type (2021-2032) Figure 53. China HIV Prevention Drug Revenue Share by Application (2021-2032) Figure 54. China HIV Prevention Drug Sales Share by Application (2021-2032) Figure 55. Asia HIV Prevention Drug Revenue Share by Type (2021-2032) Figure 56. Asia HIV Prevention Drug Sales Share by Type (2021-2032) Figure 57. Asia HIV Prevention Drug Revenue Share by Application (2021-2032) Figure 58. Asia HIV Prevention Drug Sales Share by Application (2021-2032) Figure 59. Asia HIV Prevention Drug Revenue Share by Country (2021-2032) Figure 60. Asia HIV Prevention Drug Sales Share by Country (2021-2032) Figure 61. SAMEA HIV Prevention Drug Revenue Share by Type (2021-2032) Figure 62. SAMEA HIV Prevention Drug Sales Share by Type (2021-2032) Figure 63. SAMEA HIV Prevention Drug Revenue Share by Application (2021-2032) Figure 64. SAMEA HIV Prevention Drug Sales Share by Application (2021-2032) Figure 65. SAMEA HIV Prevention Drug Revenue Share by Country (2021-2032) Figure 66. SAMEA HIV Prevention Drug Sales Share by Country (2021-2032) Figure 67. HIV Prevention Drug Value Chain Figure 68. Manufacturing Cost Structure Figure 69. HIV Prevention Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Lenacapavir
  • Cabotegravir
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Gilead Sciences
  • ViiV Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 HIV Prevention Drug Market by Type
  3. 1.2.1 Global HIV Prevention Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Lenacapavir
  5. 1.2.3 Cabotegravir
  6. 1.3 HIV Prevention Drug Market by Application
  7. 1.3.1 Global HIV Prevention Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 HIV Prevention Drug Market Dynamics
  1. 2.1 HIV Prevention Drug Industry Trends
  2. 2.2 HIV Prevention Drug Industry Drivers
  3. 2.3 HIV Prevention Drug Industry Opportunities and Challenges
  4. 2.4 HIV Prevention Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global HIV Prevention Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global HIV Prevention Drug Revenue by Region
  3. 3.2.1 Global HIV Prevention Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global HIV Prevention Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global HIV Prevention Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global HIV Prevention Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global HIV Prevention Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global HIV Prevention Drug Sales by Region
  9. 3.4.1 Global HIV Prevention Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global HIV Prevention Drug Sales by Region (2021-2026)
  11. 3.4.3 Global HIV Prevention Drug Sales by Region (2027-2032)
  12. 3.4.4 Global HIV Prevention Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global HIV Prevention Drug Revenue by Manufacturers
  2. 4.1.1 Global HIV Prevention Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global HIV Prevention Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global HIV Prevention Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global HIV Prevention Drug Sales by Manufacturers
  6. 4.2.1 Global HIV Prevention Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global HIV Prevention Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global HIV Prevention Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global HIV Prevention Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global HIV Prevention Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global HIV Prevention Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global HIV Prevention Drug Manufacturers, Product Type & Application
  13. 4.7 Global HIV Prevention Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global HIV Prevention Drug Market CR5 and HHI
  16. 4.8.2 2025 HIV Prevention Drug Tier 1, Tier 2, and Tier 3
5 HIV Prevention Drug Market by Type
  1. 5.1 Global HIV Prevention Drug Revenue by Type
  2. 5.1.1 Global HIV Prevention Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global HIV Prevention Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global HIV Prevention Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global HIV Prevention Drug Sales by Type
  6. 5.2.1 Global HIV Prevention Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global HIV Prevention Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global HIV Prevention Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global HIV Prevention Drug Price by Type
6 HIV Prevention Drug Market by Application
  1. 6.1 Global HIV Prevention Drug Revenue by Application
  2. 6.1.1 Global HIV Prevention Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global HIV Prevention Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global HIV Prevention Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global HIV Prevention Drug Sales by Application
  6. 6.2.1 Global HIV Prevention Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global HIV Prevention Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global HIV Prevention Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global HIV Prevention Drug Price by Application
7 Company Profiles
  1. 7.1 Gilead Sciences
  2. 7.1.1 Gilead Sciences Company Information
  3. 7.1.2 Gilead Sciences Business Overview
  4. 7.1.3 Gilead Sciences HIV Prevention Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Gilead Sciences HIV Prevention Drug Product Portfolio
  6. 7.1.5 Gilead Sciences Recent Developments
  7. 7.2 ViiV Healthcare
  8. 7.2.1 ViiV Healthcare Company Information
  9. 7.2.2 ViiV Healthcare Business Overview
  10. 7.2.3 ViiV Healthcare HIV Prevention Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 ViiV Healthcare HIV Prevention Drug Product Portfolio
  12. 7.2.5 ViiV Healthcare Recent Developments
8 North America
  1. 8.1 North America HIV Prevention Drug Market Size by Type
  2. 8.1.1 North America HIV Prevention Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America HIV Prevention Drug Sales by Type (2021-2032)
  4. 8.1.3 North America HIV Prevention Drug Price by Type (2021-2032)
  5. 8.2 North America HIV Prevention Drug Market Size by Application
  6. 8.2.1 North America HIV Prevention Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America HIV Prevention Drug Sales by Application (2021-2032)
  8. 8.2.3 North America HIV Prevention Drug Price by Application (2021-2032)
  9. 8.3 North America HIV Prevention Drug Market Size by Country
  10. 8.3.1 North America HIV Prevention Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America HIV Prevention Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America HIV Prevention Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe HIV Prevention Drug Market Size by Type
  2. 9.1.1 Europe HIV Prevention Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe HIV Prevention Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe HIV Prevention Drug Price by Type (2021-2032)
  5. 9.2 Europe HIV Prevention Drug Market Size by Application
  6. 9.2.1 Europe HIV Prevention Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe HIV Prevention Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe HIV Prevention Drug Price by Application (2021-2032)
  9. 9.3 Europe HIV Prevention Drug Market Size by Country
  10. 9.3.1 Europe HIV Prevention Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe HIV Prevention Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe HIV Prevention Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China HIV Prevention Drug Market Size by Type
  2. 10.1.1 China HIV Prevention Drug Revenue by Type (2021-2032)
  3. 10.1.2 China HIV Prevention Drug Sales by Type (2021-2032)
  4. 10.1.3 China HIV Prevention Drug Price by Type (2021-2032)
  5. 10.2 China HIV Prevention Drug Market Size by Application
  6. 10.2.1 China HIV Prevention Drug Revenue by Application (2021-2032)
  7. 10.2.2 China HIV Prevention Drug Sales by Application (2021-2032)
  8. 10.2.3 China HIV Prevention Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia HIV Prevention Drug Market Size by Type
  2. 11.1.1 Asia HIV Prevention Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia HIV Prevention Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia HIV Prevention Drug Price by Type (2021-2032)
  5. 11.2 Asia HIV Prevention Drug Market Size by Application
  6. 11.2.1 Asia HIV Prevention Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia HIV Prevention Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia HIV Prevention Drug Price by Application (2021-2032)
  9. 11.3 Asia HIV Prevention Drug Market Size by Country
  10. 11.3.1 Asia HIV Prevention Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia HIV Prevention Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia HIV Prevention Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA HIV Prevention Drug Market Size by Type
  2. 12.1.1 SAMEA HIV Prevention Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA HIV Prevention Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA HIV Prevention Drug Price by Type (2021-2032)
  5. 12.2 SAMEA HIV Prevention Drug Market Size by Application
  6. 12.2.1 SAMEA HIV Prevention Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA HIV Prevention Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA HIV Prevention Drug Price by Application (2021-2032)
  9. 12.3 SAMEA HIV Prevention Drug Market Size by Country
  10. 12.3.1 SAMEA HIV Prevention Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA HIV Prevention Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA HIV Prevention Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 HIV Prevention Drug Value Chain Analysis
  2. 13.1.1 HIV Prevention Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 HIV Prevention Drug Production Mode & Process
  6. 13.2 HIV Prevention Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 HIV Prevention Drug Distributors
  9. 13.2.3 HIV Prevention Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst